# Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

Source: https://onco.cc/trials/nct00189345/  
OnCo record `nct00189345` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Catumaxomab in Ovarian cancer, run by AGO Study Group, completed.

## Summary

Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients is a phase 2 interventional study registered as NCT00189345 by AGO Study Group, with 44 participants recorded, started 2004-05. Interventions recorded: anti-EpCAM x anti-CD3 (removab). Conditions recorded: Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms.

Linked to the drug Catumaxomab because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00189345
- Phase: 2
- Setting: Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
- Sponsor: AGO Study Group
- Enrolled: 44

## Sources

- ClinicalTrials.gov NCT00189345: https://clinicaltrials.gov/study/NCT00189345

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Catumaxomab](https://onco.cc/drugs/catumaxomab/)

---
JSON: https://onco.cc/api/v1/entities/nct00189345.json